9- (2,3- dihydroxy- 3- methylbutoxy)- 4- methoxy- 7H- furo(3,2- g)(1)benzopyran- 7- one

04/01/1998 - "These results indicate that in rats, byakangelicin is effective for the treatment of sugar cataracts and diabetic neuropathy and hence might be useful as a lead compound for the development of new type drugs for clinical use."
08/01/2003 - "Byakangelicin, 9-(2,3-dihydroxy-2-methylbutoxy)-4-methoxy-7H-furo[3,2-g][l]benzopyran-7-one (BKG), a component of Angelicae dahuricae Radix, is considered to be an inhibitor of aldose reductase for the treatment of diabetic cataract. "
04/01/1998 - "Cataract formation and galactitol accumulation in the lenses of rats fed a 30% galactose diet were significantly prevented by intragastric (i.g.) administration of byakangelicin at a dose of 100 mg/kg for 14 days. "
04/01/1998 - "Byakangelicin, a main furanocoumarin constituent isolated and characterized as an aldose reductase inhibitor from the roots of Angelica dahurica, was evaluated for usefulness in the treatment of galactosemic cataract and diabetic complications in animal experiments. "
04/01/1998 - "Effect of byakangelicin, an aldose reductase inhibitor, on galactosemic cataracts, the polyol contents and Na(+), K(+)ATPase activity in sciatic nerves of strepto-zotocin-induced diabetic rats."

08/01/2020 - "Byakangelicin inhibits IL-1β-induced mouse chondrocyte inflammation in vitro and ameliorates murine osteoarthritis in vivo."

08/01/2020 - "Byakangelicin inhibits IL-1β-induced mouse chondrocyte inflammation in vitro and ameliorates murine osteoarthritis in vivo."

04/01/1998 - "These results indicate that in rats, byakangelicin is effective for the treatment of sugar cataracts and diabetic neuropathy and hence might be useful as a lead compound for the development of new type drugs for clinical use."

01/01/2020 - "This study aims to explore whether byakangelicin plays a role in the development of liver fibrosis and to explore its mechanism. "
01/01/2020 - "byakangelicin has certain anti-inflammatory ability, but its effect on liver fibrosis is unclear. "
01/01/2020 - "In conclusion, byakangelicin could improve carbon tetrachloride-induced liver fibrosis and liver injury by inhibiting hepatic stellate cell proliferation and activation and suppressing hepatocyte apoptosis."
01/01/2020 - "We determined that byakangelicin has a certain ability to resist fibrosis and reduce liver cell damage in a model of carbon tetrachloride-induced liver fibrosis in mice. "